PNC Financial Services Group Inc. Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGN

PNC Financial Services Group Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,226 shares of the biopharmaceutical company’s stock after purchasing an additional 866 shares during the period. PNC Financial Services Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $14,082,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. WPG Advisers LLC raised its position in shares of Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 25 shares in the last quarter. SHP Wealth Management bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $26,000. Titan Wealth CI Ltd purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $29,000. Kemnay Advisory Services Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. Finally, Entrust Financial LLC bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $32,000. Institutional investors own 83.31% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts remain constructive ahead of Regeneron’s upcoming quarterly results, with one note saying the company is positioned to beat earnings expectations. Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
• Positive Sentiment: Guggenheim raised its price target on Regeneron, signaling continued Wall Street confidence in the stock’s longer-term upside. Guggenheim Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,000.00
• Neutral Sentiment: Multiple law firms are advertising deadlines and investor-rights notices related to the already-filed Regeneron securities class action, keeping the issue in the spotlight but not adding new allegations. The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit – REGN
• Neutral Sentiment: Additional firms, including Faruqi & Faruqi, Schall, and others, issued similar class-action reminders, which extends the legal-news flow around REGN. Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
• Negative Sentiment: Several lawsuits claim Regeneron misled investors about clinical-trial protocol and statistical risks, with one report citing a sharp selloff and an estimated $11 billion market-cap hit after the trial failure disclosure. Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure – HBSS

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $656.01 on Friday. The stock has a market cap of $69.35 billion, a price-to-earnings ratio of 15.98, a P/E/G ratio of 1.45 and a beta of 0.24. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $821.11. The stock’s 50-day moving average is $635.78 and its 200 day moving average is $714.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $8.22 EPS. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were paid a dividend of $0.94 per share. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on REGN. Wells Fargo & Company dropped their price target on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a research report on Monday, May 18th. HSBC decreased their price objective on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Morgan Stanley lowered their target price on shares of Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 8th. JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Finally, Sanford C. Bernstein cut their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $787.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.